Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 May;39(4):e183-e186.
doi: 10.1097/MPH.0000000000000822.

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy

Maurizio Ghisoli  1 , McCarley Rutledge, Philip J Stephens, Robert Mennel, Minal Barve, Meghan Manley, Bahram R Oliai, Kathleen M Murphy, Luisa Manning, Belen Gutierrez, Priyanka Rangadass, Ashli Walker, Zhaohui Wang, Donald Rao, Ned Adams, Gladice Wallraven, Neil Senzer, John Nemunaitis
Affiliations
Case Reports

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy

Maurizio Ghisoli et al. J Pediatr Hematol Oncol. 2017 May.

Abstract

Ewing sarcoma is a highly resistant disease with a <10% chance of survival at 5 years after failure of frontline chemotherapy. This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources